PT-141

Description

PT-141 Reference Material | Bremelanotide — Melanocortin Receptor Agonist

PT-141 (Bremelanotide; MW 1,025.2 g/mol) is a cyclic heptapeptide melanocortin receptor agonist that acts primarily at MC3R and MC4R in hypothalamic nuclei. Unlike PDE5 inhibitors that act peripherally, PT-141 is studied for its CNS-mediated mechanisms — specifically hypothalamic MC4R activation in the paraventricular nucleus and downstream dopaminergic pathway modulation.

Receptor Profile

PT-141 activates MC1R, MC3R, MC4R, and MC5R with varying affinity. Its primary research interest lies in MC4R pharmacology, where it serves as a reference agonist for studying paraventricular nucleus signaling, dopaminergic pathway coupling, and hypothalamic neuropeptide modulation. As a metabolite-derived cyclic peptide, its structural modifications from linear alpha-MSH produce improved receptor selectivity profile for CNS research applications.

Laboratory Research Applications

• MC3R/MC4R receptor binding and activation studies
• Hypothalamic melanocortin circuit pharmacology
• Dopaminergic pathway coupling to melanocortin receptor activation
• CNS arousal pathway mechanistic research
• Comparative melanocortin agonist selectivity studies

Specifications

• Also Known As: Bremelanotide
• Molecular Weight: 1,025.2 g/mol
• Form: Lyophilized powder
• Purity: ≥99% (HPLC verified)
• Storage: 2–8°C; protect from light

For laboratory research use only. Not for human or veterinary use.